Celldex Therapeutics is a biopharmaceutical company that applies its Immunotherapy Platform to treat various diseases. Its immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates. Celldex Therapeutics technology platform uses human monoclonal antibodies administered directly to patients to target dendritic cells and macrophages that are key cells in the immune system. Its APC Targeting Technology delivers an antigen that results in more efficient processing than a nontargeted antigen. The company develops various therapeutic human monoclonal antibody products. Its lead programs are for oncology targets. Celldex Therapeutics has two clinical programs under clinical evaluation for the therapy of cancer.